ERBB2 and cancer: A proprietary EuCODETM technology platform forms a highly stable oxime bond resulting in a novel ADC with a DAR of approximately two.23,24 In preclinical experiments, when compared in vitro against T-DM1 across a panel of cancer cell lines, ARX788 has been shown to be more potent in the HER2-positive and HER2-low cell lines and no activity against normal cardiomyocyte cells.